Evaluation of the replication and immunogenicity of recombinant human parainfluenza virus type 3 vectors expressing up to three foreign glycoproteins

Virology

Volumn 297, Issue 1, 2002, Pages 136-152

  Skiadopoulos, M H ^a   Surman, S R ^a   Riggs, J M ^a   Orvell C ^b   Collins, P L ^a   Murphy, B R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN; HEMAGGLUTININ; HN PROTEIN; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; NUCLEOTIDE; VIRUS ANTIBODY; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE INSERTION; GENE ORDER; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; IMMUNOGENICITY; MEASLES VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PARAINFLUENZA VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; VIRION; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION;

CRICETINAE; HUMAN PARAINFLUENZA VIRUS 3; MEASLES VIRUS;

EID: 0036317197     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1415     Document Type: Article

References (51)

1. Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates
2. RNA editing and hypermutation by adenosine deamination
3. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene
4. Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity
5. The rule of six, a basic feature for efficient replication of Sendai virus defective interfering RNA
6. Parainfluenza Viruses
7. Evaluation of a subcutaneously implanted chamber for antibody production in rabbits
8. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: Nucleotide sequence analysis of variants selected with monoclonal antibodies
9. In vivo antigenic studies of parainfluenza viruses
10. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV). A meeting report of the WHO Programme for Vaccine Development
11. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis
12. Recovery of infectious human parainfluenza virus type 3 from cDNA
13. Minimum protein requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3 and evaluation of the rule of six
14. Human parainfluenza virus type 3 (PIV3) expressing the hemagglutinin protein of measles virus provides a potential method for immunization against measles virus and PIV3 in early infancy
15. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys
16. Paramyxovirus RNA editing and the requirement for hexamer genome length
17. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene
18. High-level expression of a foreign gene from the most 3′-proximal locus of a recombinant Newcastle disease virus
19. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge
20. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children
21. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: The rule of six revisited
22. Highly stable expression of a foreign gene from rabies virus vectors
23. Genome nucleotide lengths that are divisible by six are not essential but enhance replication of defective interfering RNAs of the paramyxovirus simian virus 5
24. Mechanisms of loss of foreign gene expression in recombinant vesicular stomatitis viruses
25. Human parainfluenza virus induces a type-specific protective immune response
26. Parainfluenza virus type 2 haemagglutinin-neuraminidase glycoprotein characterized with monoclonal antibodies
27. Antiviral actions of interferons
28. Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies
29. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3
30. Mucosal immunization of rhesus monkeys against RSV subgroup A, subgroup B and HPIV3 using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone
31. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles
32. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus
33. A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice
34. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes
35. The bovine papilloma-virus type 1 E2 transactivator and repressor proteins use different nuclear localization signals
36. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine
37. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes
38. A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeys
39. Generation of a parainfluenza virus type 1 vaccine candidate by replacing the HN and F glycoproteins of the live-attenuated PIV3 cp45 vaccine virus with their PIV1 counterparts
40. Down-regulation of paramyxovirus hemagglutinin-neuraminidase glycoprotein surface expression by a mutant fusion protein containing a retention signal for the endoplasmic reticulum
41. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3
42. Recovery of a fully viable chimeric human parainfluenza virus (PIV) type 3 in which the hemagglutinin-neuraminidase and fusion glycoproteins have been replaced by those of PIV type 1
43. Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backbone
44. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates
45. A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challenge
46. Alternative mechanisms of interaction between homotypic and heterotypic parainfluenza virus HN and F proteins
47. Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein
48. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus
49. Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: Sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities
50. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus
51. Association of the parainfluenza virus fusion and hemagglutinin-neuraminidase glycoproteins on cell surfaces